Proliant Health & Biologicals Debuts Animal-Free Recombinant Albumin

The company, which maintains manufacturing facilities in the United States and New Zealand, utilizes precision fermentation to produce the new recombinant protein. This manufacturing approach is intended to provide consistent lot-to-lot reproducibility, a critical requirement as diagnostic platforms shift toward higher throughput and greater analytical precision. By eliminating animal- or human-derived components, the product helps manufacturers navigate complex global regulatory landscapes, including IVDR compliance, while aligning with corporate environmental, social, and governance goals.

Dr. Christopher Warner, vice president of research and development, noted that diagnostic companies are increasingly prioritizing origin-free devices to simplify testing requirements. Beyond its primary application in protein stabilization and surface blocking, the launch marks a strategic expansion for Proliant. The firm plans to follow this release with additional specialized offerings, specifically the AlbufreeTX for cell culture and AlbufreeCGT for cell and gene therapy applications.